The EPO published Patent EP3795358A1 granting Axenoll Life Sciences AG intellectual property protection for a microneedle device and its manufacturing method. The patent is classified under A61M 37/00 (microneedle devices for transdermal delivery) with supporting classifications in additive manufacturing (B33Y) and materials processing (B22F). The designated states cover all EPO member states including DE, FR, GB, IT, NL, ES, and 23 additional countries.

Manufacturers developing microneedle-based transdermal delivery systems should review this patent to assess potential freedom-to-operate implications. Healthcare providers and pharmaceutical companies utilizing microneedle technology for drug or vaccine delivery should verify their products do not infringe on the protected claims. The patent provides 20-year exclusivity from the filing date in designated territories.